Physician profile
Nidal Hasan
NPI 1326024134
$830.13
in general payments reported to CMS, 2019-2025
12 companies · $546 in 2025
The $546 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.38 · 2020: $35.06 · 2021: $48.20 · 2022: $117 · 2023: $47.59 · 2024: $20.22 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $529 · Education: $85.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $528.59 |
| Education | $85.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $224.03 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $214.59 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $158.71 | 2022-2025 | Tepezza |
| Bayer Healthcare Pharmaceuticals INC. | $56.08 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.01 | 2022-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $30.82 | 2019-2022 | |
| Abbott Laboratories | $21.00 | 2025 | Freestyle Libre 3 |
| Mannkind Corporation | $20.00 | 2023 | Afrezza |
| Sanofi-Aventis U.S. LLC | $15.93 | 2021 | |
| Dexcom, INC. | $14.05 | 2023 | Dexcom G6 Transmitter |
| Recordati_rare_diseases_inc. | $13.55 | 2025 | Isturisa |
| Merck Sharp & Dohme LLC | $12.36 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nidal Hasan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.